Product Description
All proceeds from this notebook benefit The Weekend to End Breast Cancer to support research into finding a cure…. More >>
» Read more: Breast Cancer Journal Engage Books
Product Description
All proceeds from this notebook benefit The Weekend to End Breast Cancer to support research into finding a cure…. More >>
» Read more: Breast Cancer Journal Engage Books
Skin Cancer of the eyelids poses several diagnostic and management challenge. As a referral specialist, I see these patients well after a significant progression has occurred and the diagnosis is fairly obvious. The excision and reconstruction if these tumors requires a great degree of creativity and flexibility to achieve the optimal result.
The ultraviolet radiation that is primarily responsible for malignant transformation of skin cancer are 290 to 320 nm(UV-B). The most common malignancies affecting the periocular region are basal cell carcinoma, squamous cell carcinoma, sebaceous cell carcinoma, and malignant melanoma. Basal cell carcinoma accounts for 90% of all eyelid malignancies. The tumor primarily involves the lower eyelid (50% to 66%) and the medial canthus (25% to 30%). The upper eyelid is affected in 15% of cases and the lateral canthus in 5%. Although these statistics are helpful, many skin cancers involve adjacent anatomic areas such as the forehead and cheek, and pose even greater challenges in reconstruction.
» Read more: Eyelid Skin Cancer
Standard adjuvant treatment for HER2-positive breast cancer patients, following primary surgery for their cancer, is Trastuzumab (Herceptin)–typically used in combination with chemotherapy. However, a new study by researchers at Fox Chase Cancer Center reports that it may be safe to treat these patients with both Trastuzumab and adjuvant radiation therapy.
The study will be presented at the annual meeting of the American Society for Radiation Oncology (ASTRO).
» Read more: Terramed Alliance News Safe To Treat HER2-positive Breast Cancer